{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002784","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.836783+00:00","generated_at":"2026-05-17T14:55:53.820808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers","bullets":["Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.","Cash $3.5M at June 30, 2025 (up from $1.2M at Dec 31, 2024); warrant exercise raised ~$1.8M in July.","Preclinical: SIL204 achieved 94% inhibition in pancreatic, 90% in colorectal, up to 97% in KRAS Q61H pancreatic cancer cells.","Strategic collaboration with Catalent for formulation development; Phase 2/3 trial on track for H1 2026.","Nasdaq listing maintained after 1-for-15 reverse split and panel decision; pursuing $2.5M equity threshold."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002784","json":"https://secwatch.observer/filing/0001178913-25-002784.json","markdown":"https://secwatch.observer/filing/0001178913-25-002784.md","text":"https://secwatch.observer/filing/0001178913-25-002784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/0001178913-25-002784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/zk2533609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:55:53.820808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}